Randomized, phase III trial comparing irinotecan/cisplatin (IP) with etoposide/cisplatin (EP) in patients (pts) with previously untreated, extensive-stage (ES) small cell lung cancer (SCLC)

Authors

Hanna NH; Einhorn L; Sandler A; Langer C; Hariharan S; Ansari R; Ellis P; Byrne M; Wang B; Bunn P

Journal of Clinical Oncology, Vol. 23, No. 16_suppl, pp. lba7004–lba7004

American Society of Clinical Oncology (ASCO)

June 2005

10.1200/jco.2005.23.16_suppl.lba7004

0732-183X

Peter Ellis